Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet JIVOLAR 50mg / 1000mg film-coated tablets
- Product code:
- W69553001
- Quantity:
- 14
- Indicated for:
- type 2 diabetes mellitus
- Route of administration:
- oral
- Substance:
- sitagliptin + metformin (DPP-4 inhibitor + biguanide antidiabetic)
- ATC
- A10BD07 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs
Precautions:
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Sitagliptin and metformin are used together to treat type 2 diabetes. This combination helps control blood sugar levels and is recommended for patients who cannot maintain normal glucose levels through diet and exercise alone.
Metformin reduces glucose production in the liver and improves the body's sensitivity to insulin, facilitating glucose uptake by cells. Sitagliptin, a DPP-4 inhibitor, increases incretin hormone levels, which stimulate insulin secretion and reduce glucagon release, thereby lowering blood sugar levels.
This combination is effective in reducing glycated hemoglobin (HbA1c) and preventing diabetes-related complications, such as cardiovascular diseases or kidney damage. Additionally, it has a low risk of causing hypoglycemia compared to other antidiabetic treatments.
Side effects may include nausea, diarrhea, abdominal pain, or mild respiratory infections. In rare cases, more serious reactions such as lactic acidosis (associated with metformin) or pancreatitis (associated with sitagliptin) may occur. Regular medical monitoring is essential.
Patients should strictly follow recommendations regarding diet, exercise, and medication to achieve optimal blood sugar control and reduce the risk of long-term complications.
Metformin reduces glucose production in the liver and improves the body's sensitivity to insulin, facilitating glucose uptake by cells. Sitagliptin, a DPP-4 inhibitor, increases incretin hormone levels, which stimulate insulin secretion and reduce glucagon release, thereby lowering blood sugar levels.
This combination is effective in reducing glycated hemoglobin (HbA1c) and preventing diabetes-related complications, such as cardiovascular diseases or kidney damage. Additionally, it has a low risk of causing hypoglycemia compared to other antidiabetic treatments.
Side effects may include nausea, diarrhea, abdominal pain, or mild respiratory infections. In rare cases, more serious reactions such as lactic acidosis (associated with metformin) or pancreatitis (associated with sitagliptin) may occur. Regular medical monitoring is essential.
Patients should strictly follow recommendations regarding diet, exercise, and medication to achieve optimal blood sugar control and reduce the risk of long-term complications.
General data about JIVOLAR 50mg / 1000mg
- Substance:
- sitagliptin + metformin
- Date of latest medicines list:
- 01-06-2023
- Product code:
- W69553001
- Concentration:
- 50mg / 1000mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 14
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for sitagliptin + metformin
- 50mg/1000mg
- 50mg/850mg